초록 ▼

This invention provides a method of preventing or treating a dermatologic condition including, inter alia, psoriasis, contact dermatitis, and atopic dermatitis, in a subject, the method includes the step of administering to said subject a compound comprising a lipid or phospholipid moiety bound to a

This invention provides a method of preventing or treating a dermatologic condition including, inter alia, psoriasis, contact dermatitis, and atopic dermatitis, in a subject, the method includes the step of administering to said subject a compound comprising a lipid or phospholipid moiety bound to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof, in an amount effective to treat the subject suffering from a dermatologic condition.

대표청구항 ▼

1. A method of treating a dermatologic condition in a human subject, comprising the step of administering to said subject a compound represented by the structure of the general formula (I): whereinR1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2

1. A method of treating a dermatologic condition in a human subject, comprising the step of administering to said subject a compound represented by the structure of the general formula (I): whereinR1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;R2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;Y is nothing;wherein the phospholipid moiety is directly linked to X via an amide bond;X is hyaluronic acid having intact sugar rings; andn is a number from 2 to 1000;and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. 2. The method according to claim 1, wherein R1 and R2 are both palmitoyl moieties. 3. The method according to claim 1, wherein R1 and R2 are both myristoyl moieties. 4. The method according to claim 1, wherein said dermatologic condition is psoriasis. 5. The method according to claim 1, wherein said dermatologic condition is contact dermatitis. 6. The method according to claim 1, wherein said dermatologic condition is atopic dermatitis. 7. A method of treating a dermatologic condition in a subject, comprising the step of administering to said subject a compound represented by the structure of the general formula (III): whereinR1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;R2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol;Y is nothing;X is a glycosaminoglycan having intact sugar rings; andn is a number from 2 to 1000;and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. 8. The method according to claim 7, wherein said glycosaminoglycan is hyaluronic acid. 9. The method according to claim 7, wherein said glycosaminoglycan is heparin. 10. The method according to claim 7, wherein said glycosaminoglycan is chondroitin sulfate. 11. The method according to claim 7, wherein R1 and R2 are both palmitoyl moieties. 12. The method according to claim 7, wherein R1 and R2 are both myristoyl moieties. 13. The method according to claim 7, wherein said dermatologic condition is psoriasis. 14. The method according to claim 7, wherein said dermatologic condition is contact dermatitis. 15. The method according to claim 7, wherein said dermatologic condition is atopic dermatitis. 16. The method according to claim 7, wherein said subject is a human. 17. The method according to claim 1, wherein n is a number from 2 to 100. 18. The method according to claim 1, wherein the molecular weight of said hyaluronic acid is from 5000 to 10,000 Daltons. 19. The method according to claim 1, wherein the molecular weight of said hyaluronic acid is from 10,000 to 20,000 Daltons. 20. The method according to claim 7, wherein n is a number from 2 to 100. 21. The method according to claim 7, wherein the molecular weight of said glycosaminoglycan is from 5000 to 10,000 Daltons. 22. The method according to claim 7, wherein the molecular weight of said glycosaminoglycan is from 10,000 to 20,000 Daltons.